Magnesium Taurine Cognition Randomized Trial: What the Evidence Says

Quick Answer

Magnesium Taurine Cognition Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Additionally, the failure of numerous pharmacological and non-pharmacological single-domain interventions in AD underscores the limitations of targeting single-disease mechanisms or single risk factors. [Bereczki Erika (2025); evidence level 1]
• There is a clear need for strategies addressing multiple risk factors and biological pathways simultaneously, with early intervention in the ADRD continuum being crucial for an optimal preventive effect. [Bereczki Erika (2025); evidence level 1]
• This case series presents outcomes of the first 51 patients who participated in one such program and aims to add to preliminary evidence regarding the efficacy of a personalized multimodal integrative functional medicine approach to cognitive decline in the context of prior uncontrolled and ongoing controlled trials. [Kogan Mikhail (2026); evidence level 4]
• Management of vascular risk factors (hypertension, hyperlipidemia, diabetes), tobacco and alcohol counseling, and hearing evaluation were conducted through participants' primary clinicians, consistent with standard dementia prevention guidelines. [Kogan Mikhail (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For magnesium taurine cognition randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Bereczki Erika (2025). Risk reduction and precision prevention across the Alzheimer’s disease continuum: a systematic review of clinical trials combining multidomain lifestyle interventions and pharmacological or nutraceutical approaches. DOI: 10.1016/j.tjpad.2025.100367. PMCID: PMC12627892. PMID: 41145344. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12627892/
• Kogan Mikhail (2026). The Integrative Personalized Functional Medicine Approach to Reverse Cognitive Decline: Academic Experience of the First 51 Patients Case Series. DOI: 10.1177/27536130261452680. PMCID: PMC13219804. PMID: 42221535. License: https://creativecommons.org/licenses/by-nc/4.0/ https://creativecommons.org/licenses/by-nc/4.0/ https://us.sagepub.co.... https://pmc.ncbi.nlm.nih.gov/articles/PMC13219804/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.